TLPT Rheumatology for Clinicians: Pathogenetic Axes, Master‑Switch Nodes, Minimal and Transversal Attractors, and Bio‑Pharmacology

Rheumatology within the Transversal–Longitudinal Pathogenetic Theory (TLPT) is structured by the direct translation of biochemical parameters into pathogenetic axes. Laboratory markers of inflammation (CRP, ESR, IL‑6, TNF‑α, fibrinogen, neutrophils, platelets), autoimmunity (ANA, anti‑dsDNA, rheumatoid factor, anti‑CCP, complement consumption, circulating immune complexes), proliferation (LDH, uric acid, pannus, osteophytes), fibrosis (TGF‑β, collagen, syndesmophytes), hypoxia (hemoglobin, creatinine, proteinuria, angiogenesis, VEGF), and redox imbalance (GSH, GPx, ROS, MDA, GGT, antioxidant capacity) are grouped by axes to reveal causal chains. Each parameter indicates activation or inhibition of master‑switch nodes and peripheral strategic nodes, thereby constituting minimal attractors whose depth can be assessed as superficial, medium, or profound. Clinical phenotypes—rheumatoid arthritis, lupus, ankylosing spondylitis, systemic vasculitis, and osteoarthritis—are defined by specific constellations of minimal attractors that coalesce into transversal attractors of varying depth. TLPT bio‑pharmacology provides a sequential algorithm: inhibition of NF‑κB, IL‑6/TNF‑α, mTOR/NLRP3, TGF‑β, and HIF‑1α, combined with activation of Nrf2, AMPK, and PPAR. Peripheral strategic nodes (neutrophils, fibrinogen, LDH, VEGF, ROS) amplify or stabilize master‑switch activity and are included in therapeutic modulation. This framework enables clinicians to stratify patients by attractor depth, dismantle transversal pathogenic attractors, and consolidate transversal protective attractors (MATP), thereby achieving systemic resilience in rheumatologic disease.